JP7492002B2 - Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法 - Google Patents

Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法 Download PDF

Info

Publication number
JP7492002B2
JP7492002B2 JP2022527859A JP2022527859A JP7492002B2 JP 7492002 B2 JP7492002 B2 JP 7492002B2 JP 2022527859 A JP2022527859 A JP 2022527859A JP 2022527859 A JP2022527859 A JP 2022527859A JP 7492002 B2 JP7492002 B2 JP 7492002B2
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
week
salt
aminopyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022527859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501627A5 (cg-RX-API-DMAC7.html
JP2023501627A (ja
Inventor
裕子 一ツ町
卓充 町田
真生 山田
ハロルド キール
アラム オガネシアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JP2023501627A publication Critical patent/JP2023501627A/ja
Publication of JP2023501627A5 publication Critical patent/JP2023501627A5/ja
Application granted granted Critical
Publication of JP7492002B2 publication Critical patent/JP7492002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022527859A 2019-11-13 2020-11-13 Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法 Active JP7492002B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934923P 2019-11-13 2019-11-13
US62/934,923 2019-11-13
PCT/JP2020/042410 WO2021095840A1 (en) 2019-11-13 2020-11-13 METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS

Publications (3)

Publication Number Publication Date
JP2023501627A JP2023501627A (ja) 2023-01-18
JP2023501627A5 JP2023501627A5 (cg-RX-API-DMAC7.html) 2023-11-13
JP7492002B2 true JP7492002B2 (ja) 2024-05-28

Family

ID=75912767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022527859A Active JP7492002B2 (ja) 2019-11-13 2020-11-13 Lsd1阻害剤によりlsd1関連疾患及び障害を治療する方法
JP2022519478A Active JP7379680B2 (ja) 2019-11-13 2020-11-13 テルフェニル化合物の新規な塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022519478A Active JP7379680B2 (ja) 2019-11-13 2020-11-13 テルフェニル化合物の新規な塩

Country Status (18)

Country Link
US (2) US20220387384A1 (cg-RX-API-DMAC7.html)
EP (2) EP4058018A4 (cg-RX-API-DMAC7.html)
JP (2) JP7492002B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220113390A (cg-RX-API-DMAC7.html)
CN (2) CN114728899B (cg-RX-API-DMAC7.html)
AU (2) AU2020382379B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022009221A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158442A1 (cg-RX-API-DMAC7.html)
DK (1) DK4058151T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034158T3 (cg-RX-API-DMAC7.html)
FI (1) FI4058151T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072206T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022005811A (cg-RX-API-DMAC7.html)
PH (2) PH12022551137A1 (cg-RX-API-DMAC7.html)
PL (1) PL4058151T3 (cg-RX-API-DMAC7.html)
PT (1) PT4058151T (cg-RX-API-DMAC7.html)
TW (2) TWI874490B (cg-RX-API-DMAC7.html)
WO (2) WO2021095835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
TW202329934A (zh) * 2021-09-30 2023-08-01 日商大鵬藥品工業股份有限公司 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法
WO2023076302A1 (en) 2021-10-26 2023-05-04 Astex Pharmaceuticals, Inc. Process for preparing a benzoate salt of a 1-(3-aminopyrrolidine-1-carbonyl)-3,4-diphenylbenzene compound
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090756A1 (ja) 2015-11-27 2017-06-01 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
WO2018216795A1 (ja) 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物を用いた抗腫瘍効果増強剤
WO2018216800A1 (ja) 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
WO2018221555A1 (ja) 2017-05-31 2018-12-06 大鵬薬品工業株式会社 Insm1の発現に基づくlsd1阻害剤の治療効果の予測方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US6225049B1 (en) 1992-06-17 2001-05-01 The United States Of America As Represented By The Department Of Health And Human Services Human insulinoma-associated cDNA
ATE484514T1 (de) 2001-12-13 2010-10-15 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
CA2732520A1 (en) 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012506238A (ja) 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト インスリン様増殖因子−1受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
US8367679B2 (en) 2008-12-09 2013-02-05 Merck Sharp & Dohme Corp. Biaryl carboxamides
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8765820B2 (en) 2010-04-20 2014-07-01 Universita Degli Studi Di Roma “La Sapienza” Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2711704B1 (en) 2011-05-16 2017-06-28 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
BR112014028094B1 (pt) * 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
WO2014151761A1 (en) 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
JP6521967B2 (ja) 2013-08-06 2019-05-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのkdm1a阻害剤
US9266907B2 (en) 2013-09-05 2016-02-23 King Abdullah University Of Science And Technology Tunable rare-earth fcu-metal-organic frameworks
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2018136961A1 (en) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
WO2019075327A1 (en) 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
AU2018377852B2 (en) 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
US20210069356A1 (en) 2018-01-02 2021-03-11 Celgene Corporation Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
BR112022017637A2 (pt) 2020-03-06 2022-11-08 Celgene Quanticel Res Inc Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090756A1 (ja) 2015-11-27 2017-06-01 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
WO2018216795A1 (ja) 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物を用いた抗腫瘍効果増強剤
WO2018216800A1 (ja) 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
WO2018221555A1 (ja) 2017-05-31 2018-12-06 大鵬薬品工業株式会社 Insm1の発現に基づくlsd1阻害剤の治療効果の予測方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology,2019年,30(supplement 5),v565
ClinicalTrials.gov Identifier:NCT02959437, 2016.11.09,Retrieved from the Internet:<URL:https://www.clinicaltrials.gov/ct2/show/NCT02959437>[検索日:2021年1月4日]
日本臨床74巻増刊号10(通巻第1112号)白血病学(下)-最新の基礎、臨床研究-,株式会社日本臨床社,2016年12月20日,第100-104頁

Also Published As

Publication number Publication date
BR112022008020A2 (pt) 2022-07-12
KR20220101145A (ko) 2022-07-19
HUE072206T2 (hu) 2025-10-28
KR102825246B1 (ko) 2025-06-25
MX2022005811A (es) 2022-06-08
JP7379680B2 (ja) 2023-11-14
AU2020382379A1 (en) 2022-05-05
EP4058018A4 (en) 2023-06-21
TW202128617A (zh) 2021-08-01
PT4058151T (pt) 2025-06-12
TW202128616A (zh) 2021-08-01
CA3158442A1 (en) 2021-05-20
BR112022009221A2 (pt) 2022-07-26
WO2021095835A1 (en) 2021-05-20
PL4058151T3 (pl) 2025-08-04
CA3157404A1 (en) 2021-05-20
FI4058151T3 (fi) 2025-07-16
DK4058151T3 (da) 2025-06-30
AU2020382379B2 (en) 2024-03-28
JP2022550374A (ja) 2022-12-01
EP4058151A4 (en) 2023-10-25
EP4058018A1 (en) 2022-09-21
TWI874490B (zh) 2025-03-01
EP4058151B1 (en) 2025-05-21
AU2020382214A1 (en) 2022-04-21
US12419858B2 (en) 2025-09-23
EP4058151A1 (en) 2022-09-21
ES3034158T3 (en) 2025-08-13
US20220387384A1 (en) 2022-12-08
WO2021095840A1 (en) 2021-05-20
PH12022551169A1 (en) 2024-02-19
PH12022551137A1 (en) 2023-10-09
MX2022005812A (es) 2022-08-16
US20220411368A1 (en) 2022-12-29
CN114828844A (zh) 2022-07-29
CN114728899B (zh) 2023-12-05
JP2023501627A (ja) 2023-01-18
AU2020382214B2 (en) 2023-07-06
KR20220113390A (ko) 2022-08-12
TWI874489B (zh) 2025-03-01
CN114728899A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
TWI874489B (zh) 利用lsd1抑制劑治療lsd1相關疾病及病症之方法
TWI334350B (en) Cancer treatment
BE1011980A5 (fr) Traitement du cancer avec des epothilones.
JP2024519845A5 (cg-RX-API-DMAC7.html)
WO2010086964A1 (ja) がん治療のための併用療法
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
US8349792B2 (en) Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent
EP1604991B1 (en) Antitumor effect potentiator and antitumor agent
JP2024125140A (ja) アズブジンと化学療法剤とを含む抗腫瘍医薬組成物
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
RU2826217C1 (ru) Способы лечения заболеваний и нарушений, связанных с lsd1, ингибиторами lsd1
AU2005251588B2 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
HK40078096A (en) Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
TWI440464B (zh) Anti-tumor agents, sets of groups and cancer treatment
US11179349B2 (en) Use of tumor gene methylation regulator and anti-tumor drugs
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
US20220096508A1 (en) Method of treatment and pharmaceutical dosage form
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤
WO2009119092A1 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
TW202203942A (zh) 血液癌之新穎治療法及新穎治療劑

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230911

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240516

R150 Certificate of patent or registration of utility model

Ref document number: 7492002

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150